Compare Futu Holdings Ltd (FUTU) vs Moderna, Inc. (MRNA) Price & Performance

Futu Holdings trades at $109.68, down 3.12% today amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.86, net income margin of 42.92%, and robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Recent news includes Moomoo's partnership with X's Cashtag program and a class action lawsuit deadline on August 25, 2026.

The outlook is mixed: strong profitability and analyst upside targets near 33% contrast with legal risks and technical weakness. Key risks include lawsuit outcomes and market volatility, while growth drivers are overseas expansion and trading platform adoption. Investors face a balance of high returns potential against significant headline risks.

Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.

While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.